What were we asked to look at?
The Scottish Health Technologies Group (SHTG) was asked to review the clinical effectiveness and cost effectiveness of a digital type 2 diabetes remission programme.
Why is this important
The incidence and prevalence of all types of diabetes has been steadily growing in the past 10 years in part due to better care and better detection of type 2 diabetes
- Type 2 diabetes accounts for around 88% of all diabetes cases nationally.
- There are 278,239 people living with type 2 diabetes in Scotland at the end of 2020, with approximately 20,000 new cases each year.
- Diabetes UK estimates that there are around 500,000 people in Scotland ‘at high risk’ of developing type 2 diabetes.
Health inequalities are closely linked to increased risk of both type 2 diabetes and obesity.
- Obesity, physical inactivity and an unhealthy diet as a whole are closely associated with deprivation.
- Short term mortality risk from type 2 diabetes is higher among those living in more deprived area as is the risk of serious complications including cardiovascular disease and amputation.
- Type 2 diabetes is six times more likely in people of South Asian decent and three times more likely in African and African-Caribbean people.
A digital diabetes remission programme provides a means to move people with type 2 diabetes into remission and thus reduce the health impact of diabetes for people and also reduce pressure on health and care services.
The Accelerated National Innovation Adoption (ANIA) Collaborative.